Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D
By Allan B. Haberman, PhD
A worldwide epidemic of type 2 diabetes has been in progress since the mid-1980s, according to the World Health Organization. The worldwide number of diabetics was 30 million in 1985 and is projected to increase to at least 366 million by 2030.
In the United States, an estimated 33% of people with type 2 diabetes have a serious co-morbidity associated with the disease, and almost 8% of diabetics have 4 or more of these complications, according to a report from the American Association of Clinical Endocrinologists (AACE).
In Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D, a new report from Insight Pharma Reports (formerly Advances Reports), author Allan B. Haberman, PhD, provides a strategic perspective on the field of drugs for diabetes and its complications, with an emphasis on novel and emerging drugs and therapeutic strategies.
In the United States, almost 21 million people, or 7% of the population, have diabetes, and an estimated 54 million people are in a state of prediabetes, according to the American Diabetes Association. The AACE report estimates the direct medical costs related to diabetes complications in 2006 alone amounted to $22.9 billion in the United States. Typical complications from diabetes include heart attack, chronic kidney disease, congestive heart failure, stroke, coronary heart disease, foot problems, and eye damage.
Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D gives individuals involved in the research, development, licensing, and portfolio management of current and potential diabetes therapies a complete picture of today’s therapeutic landscape, including:
- Background for understanding the nature, epidemiology, pathobiology, and cost of diabetes
- Experimental therapeutic strategies for prevention of type 1 diabetes in susceptible individuals.
- The pathogenesis of type 2 diabetes and its relationship to obesity
- Current diagnosis and treatment modalities for diabetes, types 1 and 2
- An evaluation of competitors in the diabetes market―their pipelines and specific products, alliances, therapeutic focus, and more
- Assessment of novel classes of antidiabetics that include drugs introduced into the market in 2005 and 2006, as well as drugs in still newer classes now in corporate pipelines
- Assessment of leading research and preclinical-stage drugs, and novel therapeutic strategies for type 2 diabetes
- Assessment of agents in development for diabetic complications, including a novel unifying model for induction of microvascular complications, and a novel model for induction of macrovascular complications
- The market outlook for new antidiabetic drugs
The report also includes a survey conducted by CHI in January 2007 of the views and plans of individuals at the forefront of R&D for diabetes and its complications.
The worldwide epidemic in diabetes, overwhelmingly type 2 diabetes, is driven by increased rates of obesity, especially in industrialized countries and in emerging industrial countries such as India and China, coupled with the aging of the populations in both sets of countries. A key factor in the discovery and development of successful new antidiabetic drugs is addressing the major unmet needs in type 2 diabetes, especially the need for drugs that both lower blood glucose and enable patients to lose weight, and the need to slow or reverse the decline in pancreatic beta-cell function, which is the major cause of the progression of the disease. Other unmet needs include:
- Treatments for diabetic complications
- Methods to prevent the development of type 1 diabetes in susceptible individuals
- Better strategies to prevent type 2 diabetes in prediabetic individuals
Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D, with thorough analyses of the therapeutic sectors, combined with detailed tables and figures, puts this complex disease and its sequelae in perspective.
About the Author
Allan B. Haberman, PhD, is Principal of Haberman Associates(www.biopharmconsortium.com), a consulting firm specializing in science and technology strategy for pharmaceutical, biotechnology, and other life science companies. He is also a Principal and Founder of the Biopharmaceutical Consortium, an expert team formed to assist life science companies, research groups, and emerging enterprises to identify and exploit promising, breakthrough technologies. He is also the author of numerous publications on the pharmaceutical and biotechnology industries, their technologies and products, and on the major therapeutic areas for drug discovery and development. Formerly the associate director of the Biotechnology Engineering Center at Tufts University, he received his PhD in biochemistry and molecular biology from Harvard University.